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PMACE (death, reinfarction, new onset heart failure, or rehospitalization for heart
failure): HR¼1.46 per 100 IU/L [1.23 to 1.73], p<0.001.O
S
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R
SConclusions: Peak CK-MB measurement is clinically useful to estimate infarct size
and LVEF as well as 1-year clinical outcomes after primary PCI for large anterior
STEMI.
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Background: The aim was to compare treatment and clinical outcomes of cardiogenic
shock (CS) AMI patients with and without severe renal dysfunction (SRD) on
admission.
Methods: We analyzed 676 patients with CS and AMI from PL-ACS registry.
Follow-up mortality was obtained from the government database.
Results: Patients with SRD comprised 16% of CS AMI pts. They were of higher risk
proﬁle and were less frequently treated invasively (table). Early and 2-year mortalities
are show in the table and ﬁgure.Severe renal
dysfunction
(GFR < 30)
N=106 (16%)
No severe renal
dysfunction
(GFR >= 30)
N=570 (84%) P value
Mean age, years  SD 76  9 67  12 <0.0001
Female sex, % 63 35 <0.0001
History of congestive heart
failure, %
19 10 0.0068
STEMI, % 64 76 0.0095
Primary PCI, % 39 66 <0.0001
Bypass surgery (CABG), % 1 3 0.31
Left ventricle ejection
fraction, %
31  11 37  13 0.0059
In-hospital major bleeding,
%
11 10 0.76
In-hospital stroke, % 1 2 0.76
In-hospital mortality, % 68 40 <0.0001
30-day mortality, % 80 49 <0.0001
2-year mortality, % 96 60 <0.0001
JACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT AbstrConclusions: Invasive treatment reduces mortality in patients with cardiogenic shock
and severe renal dysfunction, however only less than 5% of SRD patients is alive after
2 years.
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Background: Cardiogenic shock (CS) complicating acute coronary syndromes is
associated with increased morbidity and mortality. Although percutaneous coronary
intervention (PCI) improves clinical outcomes, it is unclear whether drug eluting
stents (DES) are superior to bare metal stents (BMS) in reducing mortality in CS. In
this study we examined the effect of DES vs. BMS on mortality in patients with CS
undergoing PCI and whether DES use confers mortality beneﬁt speciﬁcally in ST-
elevation MI (STEMI) and/or non-ST elevation MI (NSTEMI).
Methods:We examined an observational cohort of 1024 patients with CS treated with
PCI between 2005 and 2011 at 8 tertiary cardiac centers across London, UK.
Multivariate Cox-proportional hazards models were used to determine independent
predictors of mortality.
Results: 682 patients (67%) had STEMI and 342 patients (33%) had NSTEMI. DES
were used in 39% of patients with greater use in NSTEMI (37% vs. 42%, p¼0.043),
but length of stented segments were similar between both groups. When adjusting for
patient, clinical and procedural characteristics, the use of DES was an independent
predictor of 1-year mortality (HR¼0.66, 95% CI: 0.51-0.86, p¼0.002). Furthermore,
DES use conferred mortality beneﬁt in STEMI (HR¼0.63, 95% CI: 0.46-0.87,
p¼0.005), but no beneﬁt in NSTEMI (HR¼0.96, 95% CI: 0.57-1.63, p¼0.889).Conclusions: In this large registry analysis of patients with CS treated with PCI, the
use of DES was associated with a signiﬁcant reduction in 1-year mortality. This
beneﬁt appears to be seen speciﬁcally in patients with STEMI.
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Background: The use of second-generation drug-eluting stents (DES) compared with
bare metal stents (BMS) in patients with ST-segment elevation myocardial infarction
(STEMI) reduces the rate of major adverse cardiac events. There is scarce information
about the inﬂuence of gender in the performance of second generation DES in STEMI
patients. The aim of the study is to evaluate the impact of gender on the performance
of everolimus-eluting stent (EES) vs. BMS in STEMI patients at 2-year follow-up.acts/POSTER/STEMI/NSTEMI/ACS B79
Table. Unadjusted One-year Ischemic Event Rates Stratiﬁed by Presence or
Absence of Baseline Thrombocytopenia
Platelets
<150,000
(N [ 573)
Platelets
‡150,000
(N [ 9,996)
p-value
MACE 119 (21.3) 1458 (15.6) <0.0001
Death 36 (6.7) 320 (3.6) <0.0001
Cardiac death 20 (3.9) 205 (2.2) 0.02
Non-cardiac death 11 (2.0) 91 (1.0) 0.01
Myocardial infarction 53 (9.5) 716 (7.5) 0.06
Q wave infarction 13 (2.3) 173 (1.9) 0.34
Non-Q wave infarction 41 (7.4) 553 (5.7) 0.09
Target vessel
revascularization
61 (11.1) 786 (8.5) 0.01
Target lesion
revascularization
53 (9.6) 655 (7.2) 0.01
Deﬁnite/probable stent 15 (2.7) 228 (2.5) 0.63
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randomized 1498 patients with STEMI undergoing percutaneous coronary interven-
tion (PCI) to EES or BMS. For the purpose of this substudy, the patient-oriented
combined endpoint of all-cause death, any recurrent myocardial infarction and any
revascularization, target lesion revascularization and stent thrombosis rates were
analyzed according to the gender at 2-year follow-up.
Results: Out of 1498 patients included in the trial, 254 (17.0%) women were included
and randomized to BMS (n¼137, 53.9%) or EES (n¼117, 46.1%). Women were older
(67.9 vs. 59.8; p<0.01), had higher prevalence of hypertension (62.2% vs. 45.6%;
p<0.01) and a lower prevalence of smoking (36.6% vs. 79.5%; p<0.01) as compared
with men. Also women had a lower use of thrombectomy (59.1% vs. 66.4%; p¼0.02)
and IIb/IIIa inhibitor than men (44.9% vs. 53.9%, p<0.01). In contrast with men, stent
diameter was smaller in women (3.07 mm vs. 3.23 mm, p<0.01). Compliance of dual
antiplatelet therapy at one year was lower in women than in men. After adjustment per
confounders, the primary endpoint was similar between men and women (HR 0.95;
95%CI 0.66-1.37) and within women, between those treated with BMS versus EES
(HR 1.54: 95%CI 0.77-3.11). Women showed a lower rate of repeat revascularization
than men (HR 0.55; 95%CI 0.32-0.95) despite worse baseline characteristics. The
difference was driven by an outperformance of EES in women. No differences in
deﬁnitive/probable stent thrombosis (1.2% vs. 2.0% HR 0.58; 95%CI 0.17-1.94) was
observed between women and men.
Conclusions: Our substudy may suggest that EES would have a more potent anti-
proliferative effect in women suffering from STEMI as compared to men without any
safety concerns.
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Background: Intraprocedural thrombotic events (IPTE) during percutaneous coronary
intervention (PCI) are associated with adverse outcomes in patients with both non-ST-
segment elevation and ST-segment elevation acute coronary syndromes (NSTEACS/
STEMI). We have previously validated the occurrence of IPTE to be a powerful
independent predictor of early and late major adverse cardiac events (MACE) after
PCI. The extent to which individual components of IPTE are associated with adverse
events is unknown.
Methods: A total of 6,591 patients who received PCI for NSTEACS/STEMI in the
Acute Catheterization and Urgent Intervention Triage StrategY (ACUITY) and
Harmonizing Outcomes with RevascularIZatiON and Stents in Acute Myocardial
Infarction (HORIZONS-AMI) trials underwent detailed frame-by-frame core labora-
tory angiographic analysis to assess for IPTE. IPTE was deﬁned as the occurrence of
new/worsened thrombus, abrupt closure, no reﬂow/slow ﬂow, distal embolization, or
intraprocedural stent thrombosis (IPST). The independent associations of IPTE
components with death, major bleeding, and MACE at 30-days were assessed using
multivariable models.
Results: The overall incidence of IPTE was 7.8%. Among patients with IPTE, no
reﬂow/slow reﬂow was present in 58.0%, new/worsened thrombus in 35.3%, distal
embolization in 34.9%, abrupt closure in 19.8%, and IPST in 9.5% of patients. Each
IPTE component was associated with 30-day death, major bleeding, and MACE in
multivariable models (Table), with the strongest association observed for IPST.Table. Multivariate Associations of 30-day Clinical Outcomes 1 2
IPTE Component
30-day Clinical Outcome
MACE Major Bleeding Death
HR [95%CI] p-value HR [95%CI] p-value HR [95%CI] p-value
IPTE any 2.31 [1.76,
3.05]
<0.0001 1.94 [1.45,
2.60]
<0.0001 3.66 [2.21,
6.08]
<0.0001
New/worsened
thrombus
2.23 [1.46,
3.41]
0.0002 2.32 [1.52,
3.55]
<0.0001 5.72 [3.01,
10.86]
<0.0001
Abrupt closure 2.98 [1.98,
4.46]
0.0001 3.01 [2.00,
4.52]
<0.0001 4.83 [2.42,
9.67]
<0.0001
No reﬂow/slow
ﬂow
2.80 [2.00,
3.93]
<0.0001 2.04 [1.39,
2.99]
0.0003 4.24 [2.33,
7.72]
<0.0001
Distal
embolization
2.26 [1.48,
3.45]
0.0002 2.03 [1.31,
3.16]
0.0016 4.31 [2.15,
8.62]
<0.0001
IPST 6.21
[3.63,10.59]
<0.0001 4.81 [2.64,
8.76]
<0.0001 12.30
[5.32,28.41]
<0.0001
IPTE: Intraprocedural thrombotic event; IPST ¼ Intraprocedural stent thrombosis; MACE ¼
Major adverse cardiac events; HR ¼ Hazard Ratio; CI ¼ Conﬁdence Interval.
1 adjusted for age, gender, history of diabetes, history of hypertension, hyperlipidemia, current
smoking, prior MI, baseline hematocrit, baseline WBC count
2 each row represents a separate multivariate Cox regression model
B80 JACC Vol 62/18/Suppl B j October 2Conclusions: The occurrence of IPTE is not infrequent among high-risk ACS patients
undergoing PCI. The single component with the strongest association with adverse
events was IPST, which fortunately represented <10% of IPTE events overall. Future
therapeutic strategies aimed at minimizing the occurrence and consequences of IPTE
are warranted.
TCT-244
Baseline Thrombocytopenia: A Strong Predictor Of One-Year Adverse Ischemic
Events In Patients With ACS Undergoing PCI: A Pooled analysis From ACUITY
And HORIZONS-AMI Trials
Mayank Yadav1, Philippe Genereux2, Ajay J. Kirtane2, Mahesh V. Madhavan2,
Ke Xu1, Sorin Brener3, Roxana Mehran4, Gregg Stone2
1The Cardiovascular Research Foundation, New York, NY, 2Columbia University
Medical Center and the Cardiovascular Research Foundation, New York, NY, 3New
York Methodist Hospital, New York, NY, 4Mount Sinai Medical Center, New York, NY
Background: While acquired TP has consistently been associated with short- and
long-term adverse outcomes after PCI, the impact of baseline TP, however, has not
been as thoroughly investigated.
Methods: Data from 10,569 pts presenting with NSTEACS or STEMI in whom PCI
was performed was pooled from 2 large-scale randomized trials, ACUITY and
HORIZONS. Outcomes were examined according to the presence of baseline TP,
deﬁned as platelet counts <150 X 103/mm3.
Results: Baseline TP was present in 573 (5.4%) pts. Patients with baseline TP were
more likely to have diabetes, hypertension, hyperlipidemia, renal dysfunction and
prior PCI and greater number of lesions and diseased vessels. The unadjusted 1-year
rate of death (6.7% vs. 3.6%, p<0.0001), MACE (21.3% vs.15.6%, p<0.0001), target
vessel revascularization (11.1% vs. 8.5%, p¼0.01) and target lesion revascularization
(TLR; 9.6% vs. 7.2%, p¼0.01) was signiﬁcantly higher in pts with baseline TP
compared with pts with no TP. By multivariable analysis, the presence of TP at
baseline was an independent predictor of 1-year death (HR [95%CI] ¼1.71 [1.09,
2.70], p¼0.02), ischemic TLR (HR [95%CI] ¼1.42 [1.07, 1.88], p¼0.02), and major
adverse cardiac events (MACE; HR ¼1.41 [1.09, 1.82], p¼0.008).
Conclusions: The presence of baseline TP in setting of NSTEACS and STEMI pts
undergoing PCI was strongly predictive of death, ischemic TLR and MACE at 1 year.thrombosis
Data presented as n (%); CABG ¼ coronary artery bypass grafting; MACE ¼ major adverse
cardiovascular events; PCI ¼ percutaneous coronary intervention.TCT-245
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Background: Women are at high risk for mortality after ST-elevation acute
myocardial infarction (STEMI). Whether sex-disparities still exist in the treatment and
mortality of patients after STEMI remains controversial. The aim of this study was to
assess recent trends in hospital mortality and in treatment modalities for patients with
STEMI according to sex.7–November 1, 2013 j TCT Abstracts/POSTER/STEMI/NSTEMI/ACS
